Friday, 16 October 2026European Markets

B&S Group And J.MARTINS,SGPS Have A High Dividend Yield And Return On Equity In The Food Distribution Industry.

Loading stream...

(VIANEWS) - B&S Group (BSGR.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Food Distribution industry.

Financial Asset Price Forward Dividend Yield Return on Equity
B&S Group (BSGR.AS) €3.97 3.01% 11.82%
J.MARTINS,SGPS (JMT.LS) €26.86 2.19% 24.85%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. B&S Group (BSGR.AS)

3.01% Forward Dividend Yield and 11.82% Return On Equity

B&S Group S.A. distributes consumer goods worldwide. The company operates through six segments: B&S Liquors, B&S Beauty, B&S Personal Care, B&S Food, B&S Health, and B&S Retail. The B&S Liquors segment distributes branded liquors to wholesalers, consumers, and e-commerce platforms. The B&S Beauty segment distributes and sells branded fragrances and cosmetics to wholesalers, consumers, and e-commerce platforms. The B&S Personal Care segment distributes and sells branded personal and home care products to retailers. The B&S Food segment distributes a range of branded food and beverages products to duty-free, remote, retail, and maritime markets. The B&S Health segment distributes and sells branded medical products and equipment to maritime and remote markets, pharmacies, and travel clinics. The B&S Retail segment offers consumer electronics and multi-category assortments for consumers at travel locations. The company was founded in 1872 and is based in Betzdorf, Luxembourg.

Earnings Per Share

As for profitability, B&S Group has a trailing twelve months EPS of €0.31.

PE Ratio

B&S Group has a trailing twelve months price to earnings ratio of 12.79. Meaning, the purchaser of the share is investing €12.79 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.82%.

Yearly Top and Bottom Value

B&S Group's stock is valued at €3.97 at 22:40 EST, way under its 52-week high of €5.77 and way higher than its 52-week low of €3.56.

More news about B&S Group.

2. J.MARTINS,SGPS (JMT.LS)

2.19% Forward Dividend Yield and 24.85% Return On Equity

Jerónimo Martins, SGPS, S.A. operates in the food distribution and specialized retail sectors in Portugal, Poland, and Colombia. The company operates through Portugal Retail; Portugal Cash & Carry; Poland Retail; Colombia Retail; and Others, Eliminations and Adjustments segments. It operates food stores under the Biedronka name; and a chain of health and beauty stores under the Hebe banner in Poland, as well as food stores under the Ara name in Colombia. The company also operates supermarkets under the Pingo Doce banner; and cash and carry stores under the Recheio name in Portugal. In addition, it operates restaurants under the Pingo Doce name; Bem-Estar pharmacies; petrol stations; and clothing under Code brand. Further, the company operates kiosks and coffee shops under the Jeronymo name; and chocolates and confectionary retail stores under Hussel name. Additionally, the company engages in human resources top management, real estate management and administration, training, and saline brackish waters aquaculture; wholesale of fruit and vegetables; retail management, consultancy, and logistics activities; the purchase and sale of real estate; growing of crops and farming of animals; retail sale of health and beauty products; manufacture of milk and dairy products; and provision of economic and accounting, business portfolio management, financial, and sea passenger water transport services. It is also involved in the trading and distribution of consumer goods; retail and wholesale of non-food products; other business support service activities; and provision of services in the area of wholesale and retail distribution. The company was founded in 1792 and is headquartered in Lisbon, Portugal. Jerónimo Martins, SGPS, S.A. is a subsidiary of Sociedade Francisco Manuel dos Santos, SGPS, S.E.

Earnings Per Share

As for profitability, J.MARTINS,SGPS has a trailing twelve months EPS of €1.02.

PE Ratio

J.MARTINS,SGPS has a trailing twelve months price to earnings ratio of 26.33. Meaning, the purchaser of the share is investing €26.33 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.85%.

Volume

Today's last reported volume for J.MARTINS,SGPS is 112379 which is 80.34% below its average volume of 571791.

Moving Average

J.MARTINS,SGPS's worth is way above its 50-day moving average of €23.17 and way above its 200-day moving average of €21.11.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 15, 2023, the estimated forward annual dividend rate is 0.55 and the estimated forward annual dividend yield is 2.19%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 26.68B for the twelve trailing months.

More news about J.MARTINS,SGPS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com